| Literature DB >> 22973086 |
Tina Xirou1, Panagiotis G Theodossiadis, Michael Apostolopoulos, Stamatina A Kabanarou, Elias Feretis, Ioannis D Ladas, Chrysanthi Koutsandrea.
Abstract
PURPOSE: To report on the outcomes of vitrectomy and sulfur hexafluoride (SF(6)) gas tamponade for idiopathic macular holes with 2 days of face-down positioning. PATIENTS AND METHODS: This was a prospective, nonrandomized, observational sequential case-series study on 23 consecutive patients receiving macular hole surgery using 20% SF(6) and advised to stay in a face-down position for 2 days postoperatively (SF(6) group). These patients were compared to 23 consecutive patients who had previously undergone macular hole surgery, had received 14% C(3)F(8), and were advised to maintain a face-down position for 2 days (C(3)F(8) group). Patients in both groups underwent vitrectomy, internal limiting membrane peeling, and fluid gas exchange using either SF(6) or C(3)F(8.) Preoperative and postoperative data included best corrected visual acuity recorded in LogMAR units, slit-lamp biomicroscopy, and optical coherence tomography.Entities:
Keywords: C3F8 gas tamponade; SF6 gas tamponade; idiopathic macular holes
Year: 2012 PMID: 22973086 PMCID: PMC3422152 DOI: 10.2147/OPTH.S32077
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Sex and age of patients, mean distance between macular hole edges, mean diameter of the hole base, mean hole height, and the macular hole stage documented for the C3F8 group, including 95% CI and P values
| Gender (male) | 10 (43%) |
| Age (years) | Mean: 70.6 ± 6.2 |
| 95% CI: 67.9 to 73.3 | |
| Average edge (μm) | Mean: 426.2 ± 155.3 |
| 95% CI: 359.0 to 493.3 | |
| Average base (μm) | Mean: 833.2 ± 326.2 |
| 95% CI: 692.1 to 974.2 | |
| Average height (μm) | Mean: 377.5 ± 77.9 |
| 95% CI: 343.8 to 411.2 | |
| Stage | Stage 2: (n = 7, 30.4%) |
| Stage 3: (n = 12, 52.2%) | |
| Stage 4: (n = 4, 17.4%) | |
Abbreviation: CI, confidence interval.
Sex and age of patients, mean distance between macular hole edges, mean diameter of the hole base, mean of hole height, and macular hole stage documented for the SF6 group, including 95% CI and P values
| Gender (male) | 12 (52%) |
| Age (years) | Mean: 69.5 ± 7.4 |
| 95% CI: 66.3 to 72.7 | |
| Average edge (μm) | Mean: 385.0 ± 165.5 |
| 95% CI: 313.5 to 456.6 | |
| Average base (μm) | Mean: 795.1 ± 289.1 |
| 95% CI: 670.1 to 920.2 | |
| Average height (μm) | Mean: 385.6 ± 84.2 |
| 95% CI: 349.1 to 422.0 | |
| Stage | Stage 2: (n = 19, 82.6%) |
| Stage 3: (n = 16, 17.4%) | |
| Stage 4: (n = 0, 0%) | |
Abbreviation: CI, confidence interval.
Patients’ mean pre- and postoperative (6 month) best-corrected visual acuity (LogMAR) were plotted according to the gases used and macular hole stage
Notes: For the C3F8 group, the mean value was 0.62 ± 0.23 (95% CI: 0.53–0.72) with 0.28 LogMAR improvement (P < 0.0001). For the SF6 group, the mean value was 0.29 ± 0.12 (95% CI: 0.24–0.34) with 0.38 LogMAR improvement (P < 0.0001). The LogMAR improvement for the SF6 group was significantly better than that of the C3F8 group (P < 0.0001). Furthermore, for macular holes stage 2, best-corrected visual acuity was statistically significant improved (0.57 ± 0.27 [95% CI: 0.33–0.82] for the C3F8 group and 0.26 ± 0.12 [95% CI: 0.21–0.32] for the SF6 group [P = 0.023]). For patients with stage 3 macular holes, best-corrected visual acuity also significantly improved (0.61 ± 0.22 [95% CI: 0.47–0.75] for the C3F8 group and 0.39 ± 0.09 [95% CI: 0.25–0.54] for the SF6 group [P = 0.014]).
Abbreviation: CI, confidence interval.